Evidence map›Paper›PMID 41410990›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2025

Mycobacteria susceptibility to epetraborole: how far can it go?

S Singh, G D Boorgula, R-A Galvez, S K Heysell, P J McShane, M Devine, T Gumbo, S Srivastava

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

S SinghDivision of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, TX, USA.
G D BoorgulaDivision of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, TX, USA.
R-A GalvezDepartment of Medicine, Section of Pulmonary and Critical Care, University of Texas at Tyler School of Medicine, Tyler, TX, USA.
S K HeysellDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
P J McShaneDepartment of Medicine, Section of Pulmonary and Critical Care, University of Texas at Tyler School of Medicine, Tyler, TX, USA.
M DevineDepartment of Medicine, Section of Pulmonary and Critical Care, University of Texas at Tyler School of Medicine, Tyler, TX, USA.
T GumboIMPI Biotech Consortium Inc., Tateguru, Zimbabwe.
S SrivastavaDivision of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, TX, USA;, Department of Cellular and Molecular Biology, The University of Texas Health Science Centre at Tyler, Tyler, TX, USA.

Funding

Short course combination regimens for treatment of Mycobacterium avium pulmonary disease: a translational bench-to-bedside approachR01AI179827 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI Shashi Kant · 2024 to 2026
$1.7M
PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TBR01HD099756 · NICHD · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI KANT, SHASHI · 2019 to 2023
$1.6M
Reinforcing old warriors to treat Mycobacterium kansasii in shorter durationR21AI148096 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI KANT, SHASHI · 2020 to 2021
$413k
NIAID NIH HHS R01 AI179827NIAID NIH HHS R21 AI148096NICHD NIH HHS R01 HD099756
6 · The paper itself

Abstract

<sec><title>BACKGROUND</title>New chemotherapeutic agents are needed for the treatment of drug-resistant

Indexed as

Antitubercular AgentsBoron CompoundsHumansMicrobial Sensitivity TestsMycobacterium abscessusMycobacterium avium ComplexMycobacterium kansasiiMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsBoron Compounds

Identifiers

PMID41410990
PMCPMC13641685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.